Effect of HPV on tumor expression levels of the most commonly used markers in HNSCC
Language English Country United States Media print-electronic
Document type Comparative Study, Journal Article
PubMed
26666815
DOI
10.1007/s13277-015-4569-6
PII: 10.1007/s13277-015-4569-6
Knihovny.cz E-resources
- Keywords
- Head and neck cancer, Human papillomavirus, Kaplan-Meier analysis, Tumor markers,
- MeSH
- DNA, Viral genetics MeSH
- Adult MeSH
- Papillomavirus Infections complications virology MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger genetics MeSH
- Survival Rate MeSH
- Biomarkers, Tumor genetics MeSH
- Head and Neck Neoplasms etiology pathology MeSH
- Follow-Up Studies MeSH
- Papillomaviridae genetics MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Prognosis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Carcinoma, Squamous Cell etiology pathology MeSH
- Neoplasm Staging MeSH
- Gene Expression Profiling MeSH
- Case-Control Studies MeSH
- Neoplasm Grading MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Names of Substances
- DNA, Viral MeSH
- RNA, Messenger MeSH
- Biomarkers, Tumor MeSH
Approximately 90 % of head and neck cancers are squamous cell carcinomas (HNSCC), and the overall 5-year survival rate is not higher than 50 %. There is much evidence that human papillomavirus (HPV) infection may influence the expression of commonly studied HNSCC markers. Our study was focused on the possible HPV-specificity of molecular markers that could be key players in important steps of cancerogenesis (MKI67, EGF, EGFR, BCL-2, BAX, FOS, JUN, TP53, MT1A, MT2A, VEGFA, FLT1, MMP2, MMP9, and POU5F). qRT-PCR analysis of these selected genes was performed on 74 biopsy samples of tumors from patients with histologically verified HNSCC (22 HPV-, 52 HPV+). Kaplan-Meier analysis was done to determine the relevance of these selected markers for HNSCC prognosis. In conclusion, our study confirms the impact of HPV infection on commonly studied HNSCC markers MT2A, MMP9, FLT1, VEGFA, and POU5F that were more highly expressed in HPV-negative HNSCC patients and also shows the relevance of studied markers in HPV-positive and HPV-negative HNSCC patients.
See more in PubMed
Biochim Biophys Acta. 2005 May 25;1755(1):37-69 PubMed
Mol Cancer Res. 2010 Feb;8(2):266-77 PubMed
Cancer Res. 1993 Oct 1;53(19):4477-80 PubMed
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 PubMed
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):701-9 PubMed
Tumour Biol. 2015 Dec;36(12):9929-39 PubMed
Int J Oral Surg. 1983 Dec;12(6):418-24 PubMed
FEBS Lett. 2006 Feb 20;580(5):1235-8 PubMed
Stem Cells Int. 2013;2013:319489 PubMed
Radiother Oncol. 2013 Sep;108(3):397-402 PubMed
Int J Cancer. 2003 Apr 10;104(3):336-44 PubMed
Oral Oncol. 2013 Jun;49(6):560-6 PubMed
Head Neck. 2015 Sep;37(9):1310-8 PubMed
APMIS. 2010 Jun;118(6-7):510-9 PubMed
N Engl J Med. 2007 May 10;356(19):1944-56 PubMed
Metallomics. 2014 Jan;6(1):55-68 PubMed
Hum Mutat. 2003 Mar;21(3):252-7 PubMed
Lancet Oncol. 2010 Aug;11(8):781-9 PubMed
Clin Cancer Res. 2008 Jan 15;14(2):366-9 PubMed
J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006 PubMed
Emerg Microbes Infect. 2014 Sep;3(9):e63 PubMed
Nat Genet. 1995 Oct;11(2):210-2 PubMed
Biochem Biophys Res Commun. 2003 Mar 21;302(4):904-15 PubMed
Radiother Oncol. 2014 Dec;113(3):337-44 PubMed
Am J Surg Pathol. 2011 Sep;35(9):1343-50 PubMed
PLoS One. 2014 Jan 27;9(1):e87207 PubMed
Br J Cancer. 1999 Oct;81(4):712-20 PubMed
Int J Cancer. 2014 Nov 15;135(10):2404-12 PubMed
Anticancer Res. 2009 May;29(5):1467-74 PubMed
Int J Cancer. 2009 Jul 15;125(2):362-6 PubMed
Oncogene. 2001 Nov 26;20(54):7874-87 PubMed
CA Cancer J Clin. 2015 Mar;65(2):87-108 PubMed
Oral Oncol. 1999 May;35(3):227-33 PubMed
Br J Cancer. 2010 Nov 9;103(10):1510-7 PubMed
FEBS Lett. 2011 Jan 21;585(2):421-8 PubMed
Oral Oncol. 2014 Mar;50(3):168-77 PubMed
Oncogene. 2009 Jul 30;28(30):2723-37 PubMed
J Surg Oncol. 2014 Sep;110(4):393-9 PubMed
PLoS One. 2014 Jan 08;9(1):e85346 PubMed
Acta Oncol. 2014 May;53(5):637-45 PubMed
Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S89-96 PubMed
J Pathol. 2007 Nov;213(3):283-93 PubMed
Br J Oral Maxillofac Surg. 2007 Mar;45(2):116-22 PubMed
Cell Mol Life Sci. 1999 Apr;55(4):639-52 PubMed
Tumour Biol. 2011 Oct;32(5):941-50 PubMed
J Oral Pathol Med. 2008 Nov;37(10):593-8 PubMed
Oncology (Williston Park). 2010 Sep;24(10):915-9, 924 PubMed
J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 PubMed
Clin Cancer Res. 2004 May 1;10(9):3110-6 PubMed
Semin Radiat Oncol. 2012 Apr;22(2):128-42 PubMed
Head Neck. 2006 Oct;28(10):916-25 PubMed
